, Volume 75, Issue 15, pp 1815–1822 | Cite as

Flibanserin: First Global Approval

  • Emma D. Deeks
AdisInsight Report


Flibanserin (Addyi™) is chemically described as a benzimidazole and is being developed by Sprout Pharmaceuticals for the treatment of hypoactive sexual desire disorder (HSDD). The drug has a high affinity for serotonin 5-HT1A and 5-HT2A receptors (5-HT1A agonist/5-HT2A antagonist) and is believed to treat HSDD by increasing levels of dopamine and noradrenaline and lowering levels of serotonin in the brain. Flibanserin has been approved in the USA for the treatment of premenopausal women with acquired, generalized HSDD. Earlier phase III development of the agent for HSDD in the EU and Canada had been discontinued by Boehringer Ingelheim, following regulatory feedback. Boehringer Ingelheim had also evaluated flibanserin for the treatment of depression but, due to displaying very mild antidepressant activity, its development in this indication was discontinued. This article summarizes the milestones in the development of flibanserin leading to its first approval for HSDD.


Premenopausal Woman Sexual Dysfunction Sexual Desire Female Sexual Function Index Etravirine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. E. D. Deeks is a salaried employee of Adis, Springer SBM.


  1. 1.
    Jordan R, Hallam TJ, Molinoff P, et al. Developing treatments for female sexual dysfunction. Clin Pharmacol Ther. 2011;89(1):137–41.CrossRefPubMedGoogle Scholar
  2. 2.
    Lodise NM. Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communicating with patients on sexual health. Pharmacotherapy. 2013;33(4):411–21.CrossRefPubMedGoogle Scholar
  3. 3.
    American Psychiatric Association. Diagnostic and statistical manual pf mental disorders. 4th ed. Washington, DC: American Psychiatric Press; 2000.Google Scholar
  4. 4.
    IsHak WW, Tobia G. DSM-5 changes in diagnostic criteria of sexual dysfunctions. Reprod Sys Sex Disord. 2013;2(2):122. doi: 10.4172/2161-038X.1000122.Google Scholar
  5. 5.
    US FDA. FDA approves first treatment for sexual desire disorder. Addyi approved to treat premenopausal women [media release]. 18 Aug 2015.
  6. 6.
    Sprout Pharmaceuticals Inc. Addyi (flibanserin) tablets, for oral use: US prescribing information 2015. Accessed 20 Aug 2015.
  7. 7.
    Hayes E. FDA position on female sexual desire disorders. Pharm Approvals Monthly. Posted 18 June 2013. Article ID 06130601002 [online resource].Google Scholar
  8. 8.
    Boehringer Ingelheim. Following regulatory feedback Boehringer Ingelheim decides to discontinue flibanserin development [media release]. 8 Oct 2010.
  9. 9.
    Sprout Pharmaceuticals. Sprout Pharmaceuticals confirms resubmission to FDA of flibanserin for treatment of pre-menopausal hypoactive sexual desire disorder [media release]. 26 Jun 2013.
  10. 10.
    Sprout Pharmaceuticals. Sprout Pharmaceuticals appeals FDA decision on New Drug Application for flibanserin to treat hypoactive sexual desire disorder in premenopausal women [media release]. 11 Dec 2013.
  11. 11.
    Sprout Pharmaceuticals. Sprout Pharmaceuticals resubmits flibanserin New Drug Application for the treatment of hypoactive sexual desire disorder in premenopausal women [media release]. 17 Feb 2015.
  12. 12.
    Sprout Pharmaceuticals. Sprout Pharmaceuticals receives clear guidance from FDA on path forward to resubmit New Drug Application for flibanserin, the first potential medical treatment for hypoactive sexual desire disorder in premenopausal women [media release]. 11 Feb 2014.
  13. 13.
    US FDA. NDA 22526 Addyi™ (flibanserin): Risk Evaluation and Mitigation Strategy (REMS). 2015. Accessed 7 Sep 2015.
  14. 14.
    Borsini F, Giraldo E, Monferini E, et al. BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex. Naunyn Schmiedebergs Arch Pharmacol. 1995;352(3):276–82.PubMedGoogle Scholar
  15. 15.
    Marazziti D, Palego L, Giromella A, et al. Region-dependent effects of flibanserin and buspirone on adenylyl cyclase activity in the human brain. Int J Neuropsychopharm. 2002;5(2):131–40.CrossRefGoogle Scholar
  16. 16.
    Borsini F, Ceci A, Bietti G. BIMT 17, a 5-HT1A receptor agonist/5-HT2A receptor antagonist, directly activates postsynaptic 5-HT inhibitory responses in the rat cerebral cortex. Naunyn Schmiedebergs Arch Pharmacol. 1995;352:283–90.PubMedGoogle Scholar
  17. 17.
    Rueter LE, Blier P. Electrophysiological examination of the effects of sustained flibanserin administration on serotonin receptors in rat brain. Br J Pharmacol. 1999;126(3):627–38.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Stahl SM. Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. CNS Spectr. 2015;20(1):1–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Invernizzi RW, Sacchetti G, Parini S, et al. Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br J Pharmacol. 2003;139(7):1281–8.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Allers KA, Dremencov E, Ceci A, et al. Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: a microdialysis study. J Sex Med. 2010;7(5):1757–67.CrossRefPubMedGoogle Scholar
  21. 21.
    Ferger B, Shimasaki M, Ceci A, et al. Flibanserin, a drug intended for treatment of hypoactive sexual desire disorder in pre-menopausal women, affects spontaneous motor activity and brain neurochemistry in female rats. Naunyn Schmiedebergs Arch Pharmacol. 2010;381(6):573–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Gelez H, Clement P, Compagnie S, et al. Brain neuronal activation induced by flibanserin treatment in female rats. Psychopharmacology. 2013;230(4):639–52.CrossRefPubMedGoogle Scholar
  23. 23.
    Aubert Y, Gustison ML, Gardner LA, et al. Flibanserin and 8-OH-DPAT implicate serotonin in association between female marmoset monkey sexual behavior and changes in pair-bond quality. J Sex Med. 2012;9(3):694–707.CrossRefPubMedGoogle Scholar
  24. 24.
    Kennedy S. Flibanserin: initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder. J Sex Med. 2010;7(10):3449–59.CrossRefPubMedGoogle Scholar
  25. 25.
    Troconiz IF, Boland K, Staab A. Population pharmacokinetic/pharmacodynamic model for the sedative effects of flibanserin in healthy volunteers. Pharm Res. 2012;29(6):1518–29.CrossRefPubMedGoogle Scholar
  26. 26.
    Clayton A, Jayne C, Jacobs M, et al. Efficacy of flibanserin as a potential treatment for hypoactive sexual desire disorder in North American premenopausal women: results from the DAHLIA trial [abstract PS-02-008]. J Sex Med. 2009;6(Suppl 5):408–9.Google Scholar
  27. 27.
    Thorp J, Simon J, Dattani D, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med. 2012;9(3):793–804.CrossRefPubMedGoogle Scholar
  28. 28.
    DeRogatis LR, Komer L, Katz M, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET study. J Sex Med. 2012;9(4):1074–85.CrossRefPubMedGoogle Scholar
  29. 29.
    Katz M, DeRogatis LR, Ackerman R, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med. 2013;10(7):1807–15.CrossRefPubMedGoogle Scholar
  30. 30.
    Nappi R, Dean J, van Lunsen R, et al. Efficacy of flibanserin as a potential treatment for hypoactive sexual desire disorder in European premenopausal women: results from the ORCHID trial [abstract no. PS-02-009]. J Sex Med. 2009;6(Suppl 5):409.Google Scholar
  31. 31.
    Goldfischer ER, Breaux J, Katz M, et al. Continued efficacy and safety of flibanserin in premenopausal women with hypoactive sexual desire disorder (HSDD): results from a randomized withdrawal trial. J Sex Med. 2011;8(11):3160–70.CrossRefPubMedGoogle Scholar
  32. 32.
    Jayne C, Simon JA, Taylor LV, et al. Open-label extension study of flibanserin in women with hypoactive sexual desire disorder. J Sex Med. 2012;9(12):3180–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Simon JA, Kingsberg SA, Shumel B, et al. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause. 2014;21(6):633–40.CrossRefPubMedGoogle Scholar
  34. 34.
    Simon JA, Barbour K, Symons J. Hypoactive sexual desire disorder (HSDD): consistent efficacy and safety of flibanserin treatment in both pre and postmenopausal women [abstract]. J Gen Int Med. 2013;28:S93.CrossRefGoogle Scholar
  35. 35.
    Sprout Pharmaceuticals Inc. Flibanserin evaluation over 28 additional weeks in hypoactive sexual desire disorder [ identifier NCT00601367]. 2014. Accessed 7 Sep 2015.
  36. 36.
    Natarajan K, Sicard E, Kay GG, et al. Efficacy and sedation-related safety of flibanserin in premenopausal women [abstract no. 117]. J Sex Med. 2015;12(Suppl 2):143.Google Scholar
  37. 37.
    Croft H, Mulroy A, Sambunaris A, et al. A 12-week, randomized, double-blind, placebo-controlled, phase III safety trial of flibanserin tablets (100 MG Q.D.) in women taking a selective serotonin or serotoninnorepinephrine reuptake inhibitor [abstract no. 18]. J Sex Med. 2012;9(9 Suppl 3):168.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations